pipeline: archive 1 source(s) post-merge

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

inbox/archive/health/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md

@@ -0,0 +1,57 @@
+---
+type: source
+title: "Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999–2023"
+author: "JACC study authors (multiple)"
+url: https://www.jacc.org/doi/10.1016/j.jacc.2025.09.1607
+date: 2025-10-01
+domain: health
+secondary_domains: []
+format: journal-article
+status: processed
+priority: high
+tags: [hypertension, treatment-adherence, control-rates, cardiometabolic, diabetes, hyperlipidemia, United-States, SDOH, behavioral-health, JACC]
+---
+
+## Content
+
+**JACC longitudinal study** tracking prevalence, treatment, and CONTROL of hypertension, diabetes, and hyperlipidemia in US adults from 1999–2023.
+
+**Key findings:**
+
+**Hypertension:**
+- Affects **1 in 2 US adults** under 2017 ACC/AHA criteria
+- Prevalence: **23.4%** ages 18–39, **52.5%** ages 40–59, **71.6%** ages 60+
+- **Little change in prevalence between 2009 and 2023** despite decades of awareness campaigns
+- Among treated patients: only **23.4%** (95% CI: 21.5%-25.2%) achieved BP control in 2021–2023 by updated criteria
+
+**Cardiometabolic triple (hypertension + diabetes + hyperlipidemia):**
+- "Treatment and control of these conditions improved during the 2000s, but progress has **plateaued in subsequent years**"
+- "The proportion of individuals with hypertension, diabetes, and hyperlipidemia achieving control of all 3 conditions **did not exceed 30%** at any point during the study period"
+
+**Implication:**
+Despite the availability of effective generic medications for all three conditions (antihypertensives since 1980s, statins since late 1990s/generics, metformin/sulfonylureas for diabetes), the US healthcare system consistently fails to achieve BP, lipid, and glycemic control simultaneously in the most at-risk patients.
+
+## Agent Notes
+
+**Why this matters:** This is the companion to the JACC CVD mortality trends archive. While the mortality archive shows WHAT happened (hypertension mortality doubled), this archive explains WHY: treatment and control rates have stagnated at very low levels despite effective, affordable drugs. Only 23.4% of treated hypertensives achieve BP control. This is the clinical face of Belief 2's "80-90% non-clinical" thesis — drugs are prescribed, but the non-clinical factors (medication adherence, food environment, lifestyle, social stress, healthcare access and continuity) overwhelm the pharmacological intervention.
+
+**What surprised me:** The 23.4% control rate is shockingly low. I had assumed statin success and antihypertensive effectiveness would translate to better population-level control. The fact that we've had affordable antihypertensives for 30-40 years and only 23.4% of treated patients achieve control suggests this is a deeply structural problem, not a drug availability problem.
+
+**What I expected but didn't find:** Evidence that control rates are improving meaningfully post-2020 with telehealth expansion, remote BP monitoring, and care management programs. The data through 2023 shows stagnation, not improvement.
+
+**KB connections:**
+- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — this is the clinical-trial-level evidence for the 80-90% claim: 76.6% treatment failure despite effective drugs
+- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] — the SDOH screening/action gap explains why these patients aren't being treated at the SDOH level
+- social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day — social isolation → adherence failure → treatment non-control
+- Big Food companies engineer addictive products by hacking evolutionary reward pathways — food environment → persistent hypertension despite medication
+
+**Extraction hints:**
+- "Only 23.4% of treated US hypertensives achieved blood pressure control in 2021-2023, and the proportion simultaneously controlling hypertension, diabetes, and hyperlipidemia never exceeded 30% between 1999-2023, demonstrating that pharmacological availability is not the binding constraint in cardiometabolic disease management"
+- This claim should be paired with the hypertension mortality doubling claim — cause (treatment failure) and effect (doubled mortality) are in two separate archives
+
+**Context:** JACC study published October 2025, using NHANES longitudinal survey data. NHANES is the gold standard for US health surveillance — nationally representative, continuous since 1999. The 2021-2023 data is the most recent available.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
+WHY ARCHIVED: Provides the clinical-operational evidence for Belief 2 — drugs that work are not achieving outcomes at population level. The 23.4% control rate is the single most striking number for the "medicine fails despite availability" argument.
+EXTRACTION HINT: Extract as a claim about cardiometabolic risk factor control failure, explicitly framing the 23.4% control rate as evidence that behavioral/SDOH barriers overwhelm pharmacological availability. Extract alongside the hypertension mortality doubling claim (queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md) — they form a cause/effect pair.